Min Yan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Min Yan has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Chengqi Gao
State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China
27 shared publications - Chunhao Deng
Centre of Reproduction, Development and Aging, Faculty of Health Sciences, University of Macau, Macau SAR, China
27 shared publications - Danyang Wang
State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China
27 shared publications - Guokai Chen
Department of Biomedical Sciences, Faculty of Health Sciences, University of Macau
27 shared publications - Jianeng Zhang
State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China
27 shared publications - Jing Chen
Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China
27 shared publications
Latest Publications
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 5 from Androgen Signaling Contributes to Sex Differences in Cancer by Inhibiting NF-κB Activation in T Cells and Suppressing Antitumor Immunity
Clinical characteristics for melanoma cohort analyzed sex difference of survival in patients treated with anti-PD-1 antibody
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 5 from Androgen Signaling Contributes to Sex Differences in Cancer by Inhibiting NF-κB Activation in T Cells and Suppressing Antitumor Immunity
Clinical characteristics for melanoma cohort analyzed sex difference of survival in patients treated with anti-PD-1 antibody
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Androgen Signaling Contributes to Sex Differences in Cancer by Inhibiting NF-κB Activation in T Cells and Suppressing Antitumor Immunity
Clinical characteristics for the NSCLC cohort analyzed the correlation between testosterone levels, prognosis and T cell infiltration
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Androgen Signaling Contributes to Sex Differences in Cancer by Inhibiting NF-κB Activation in T Cells and Suppressing Antitumor Immunity
Clinical characteristics for the NSCLC cohort analyzed the correlation between testosterone levels, prognosis and T cell infiltration
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from Androgen Signaling Contributes to Sex Differences in Cancer by Inhibiting NF-κB Activation in T Cells and Suppressing Antitumor Immunity
Clinical characteristics for the NSCLC cohort analyzed sex difference of survival in patients treated with anti-PD-1 antibody
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from Androgen Signaling Contributes to Sex Differences in Cancer by Inhibiting NF-κB Activation in T Cells and Suppressing Antitumor Immunity
Clinical characteristics for the NSCLC cohort analyzed sex difference of survival in patients treated with anti-PD-1 antibody
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure Legends from Androgen Signaling Contributes to Sex Differences in Cancer by Inhibiting NF-κB Activation in T Cells and Suppressing Antitumor Immunity
Supplementary Figure 1 and 2 Legends
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure Legends from Androgen Signaling Contributes to Sex Differences in Cancer by Inhibiting NF-κB Activation in T Cells and Suppressing Antitumor Immunity
Supplementary Figure 1 and 2 Legends
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Data from Androgen Signaling Contributes to Sex Differences in Cancer by Inhibiting NF-κB Activation in T Cells and Suppressing Antitumor Immunity
Sex is known to be an important factor in the incidence, progression, and outcome of cancer. A better understanding of the underlying mechanisms could help improve cancer prevention and treatment. Here, we demonstrated a crucial role of antitumor immunity in the sex differences in cancer. Consistent with observations in human cancers, male mice showed accelerated tumor progression compared with females, but these differences were not observed in immunodeficient mice. Androgen signaling suppressed T-cell immunity against cancer in males. Mechanistically, androgen-activated androgen receptor upregulated expression of USP18, which inhibited TAK1 phosphorylation and the subsequent activation of NF-κB in antitumor T cells. Reduction of testosterone synthesis by surgical castration or using the small-molecular inhibitor abiraterone significantly enhanced the antitumor activity of T cells in male mice and improved the efficacy of anti–PD-1 immunotherapy. Together, this study revealed a novel mechanism contributing to sex differences in cancer. These results indicate that inhibition of androgen signaling is a promising approach to improve the efficacy of immunotherapy in males.Significance:Androgen signaling induces immunosuppression in cancer by blocking T-cell activity through upregulation of USP18 and subsequent inhibition of NF-κB activity, providing a targetable axis to improve antitumor immunity in males.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Androgen Signaling Contributes to Sex Differences in Cancer by Inhibiting NF-κB Activation in T Cells and Suppressing Antitumor Immunity
Sex is known to be an important factor in the incidence, progression, and outcome of cancer. A better understanding of the underlying mechanisms could help improve cancer prevention and treatment. Here, we demonstrated a crucial role of antitumor immunity in the sex differences in cancer. Consistent with observations in human cancers, male mice showed accelerated tumor progression compared with females, but these differences were not observed in immunodeficient mice. Androgen signaling suppressed T-cell immunity against cancer in males. Mechanistically, androgen-activated androgen receptor upregulated expression of USP18, which inhibited TAK1 phosphorylation and the subsequent activation of NF-κB in antitumor T cells. Reduction of testosterone synthesis by surgical castration or using the small-molecular inhibitor abiraterone significantly enhanced the antitumor activity of T cells in male mice and improved the efficacy of anti–PD-1 immunotherapy. Together, this study revealed a novel mechanism contributing to sex differences in cancer. These results indicate that inhibition of androgen signaling is a promising approach to improve the efficacy of immunotherapy in males.Significance:Androgen signaling induces immunosuppression in cancer by blocking T-cell activity through upregulation of USP18 and subsequent inhibition of NF-κB activity, providing a targetable axis to improve antitumor immunity in males.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure Legends from Androgen Signaling Contributes to Sex Differences in Cancer by Inhibiting NF-κB Activation in T Cells and Suppressing Antitumor Immunity
Supplementary Figure 1 and 2 Legends
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure Legends from Androgen Signaling Contributes to Sex Differences in Cancer by Inhibiting NF-κB Activation in T Cells and Suppressing Antitumor Immunity
Supplementary Figure 1 and 2 Legends